BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30

• Results From The Sidney Kimmel Cancer Center At Thomas Jefferson University

  April 20, 2015

   · 

  3 min read
• Drug Development

  Immunocore Limited Announces Positive Clinical Trial Data For Novel First-in-Class Immunotherapy At AACR Annual Meeting 2015

  April 20, 2015

   · 

  6 min read
• Pharm Country

  Integra LifeSciences To Participate In Three Investor Conferences In May

  April 20, 2015

   · 

  2 min read
• Biotech Bay

  Guardant Health Presents Data On Biopsy-Free Tumor Genomic Profiling Of More Than 2000 Clinical Samples Via Guardant360

  April 20, 2015

   · 

  3 min read
• Minomic Release: New Australian Prostate Cancer Screening Technology Achieves “Outstanding” Results On Key US Pilot Study

  April 20, 2015

   · 

  4 min read
• Business

  PharmaCyte Biotech Finalizes International Diabetes Consortium To Cure Diabetes

  April 20, 2015

   · 

  11 min read
• Drug Development

  Pembrolizumab, Merck & Co.'s Investigational Anti PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival And Overall Response Rate Compared To Ipilimumab, An Anti-CTLA-4 Therapy, In A Phase 3 Study Of Patients With Advanced Melanoma

  April 20, 2015

   · 

  9 min read
• Policy

  Seattle Genetics, Inc. Release: FDA Accepts Supplemental BLA And Grants Priority Review For ADCETRIS (Brentuximab Vedotin) In The AETHERA Setting For The Post-Transplant Consolidation Treatment Of Hodgkin Lymphoma Patients At High Risk Of Relapse

  April 20, 2015

   · 

  12 min read
• Business

  Vanda Pharmaceuticals, Inc. Announces The Appointment Of Chief Commercial Officer

  April 20, 2015

   · 

  3 min read
• Drug Development

  Epizyme To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma

  April 20, 2015

   · 

  3 min read